Solesence
Solesence's revenue rose 18.6% to $62 million in fiscal 2025. Its operating margin was 4.2%, up from 3.8% a year earlier. The diluted share count rose 11.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2020 to 2025, earnings per share grew 5.9% a year and net income 22.9% a year, as new shares raised the share count by 89% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1 | 2 | 2 | 1 | 1 |
| Debt incl. finance leases | — | 1 | — | — | — |
| Net debt (negative means net cash) | — | −1 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.2x | — | — | — |
| Interest coverage | 2.2x | −5.9x | −4.9x | 3.0x | 2.5x |
| Current ratio | 1.6x | 1.2x | 0.9x | 1.0x | 1.8x |
| Quick ratio | 0.8x | 0.6x | 0.4x | 0.3x | 0.7x |
Cash flow
Projections
Project Solesence's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4,785 of Solesence shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 24, 2025 | Whitmore R JanetDirector | Bought | 2,500 | $1.91 | $4,785 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −8.2% | 35.4% | — |
| Altman Z'' | −12.07 | −7.10 | −4.77 |
| Accruals ratio | −9.0% | −2.3% | 24.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Solesence side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Solesence | FY25 | 18.6% | 4.2% | — | — | — | — | |
| FitLife Brands | FY25 | 26.4% | 12.3% | 9.1% | — | — | — | Compare |
| Natural Health Trends | FY25 | −7.4% | −4.5% | −15.2% | — | — | — | Compare |
| Mannatech | FY25 | −8.3% | −0.4% | −4.0% | — | −4.1x | 2 | Compare |
| Bioharvest Sciences | FY25 | 37.0% | −16.2% | −27.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 11 | 12 | 14 | 12 | 17 | 30 | 37 | 37 | 52 | 62 |
| Revenue growth | 4.6% | 15.7% | 13.8% | −11.9% | 36.9% | 72.1% | 26.6% | −0.1% | 40.4% | 18.6% |
| Gross profit | 3 | 4 | 3 | 3 | 6 | 9 | 8 | 7 | 13 | 17 |
| Research and development | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 |
| Operating income | −1 | −1 | −2 | −3 | 2 | 3 | −2 | −4 | 2 | 3 |
| Net income | −1 | −1 | −2 | −3 | 1 | 2 | −3 | −5 | 1 | 3 |
| Diluted EPS (US$) | −0.04 | −0.03 | −0.06 | −0.08 | 0.03 | 0.05 | −0.05 | −0.10 | 0.02 | 0.04 |
| Diluted shares (millions) | 31 | 31 | 34 | 37 | 38 | 47 | 49 | 50 | 65 | 73 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −1 | −1 | −3 | −2 | 2 | −2 | −2 | 2 | −9 |
| Capital expenditure | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 1 | 5 | — |
| Free cash flow | −0 | −1 | −2 | −4 | −3 | 0 | −4 | −3 | −3 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 |
| Debt incl. finance leases | — | — | — | — | 2 | — | 1 | — | — | — |
| Total assets | 5 | 6 | 7 | 9 | 14 | 28 | 34 | 31 | 45 | 46 |
| Total liabilities | 2 | 3 | 5 | 8 | 11 | 21 | 29 | 31 | 35 | 32 |
| Shareholders' equity | 3 | 3 | 1 | 2 | 3 | 8 | 5 | 0 | 10 | 14 |
| Margins and ratios | ||||||||||
| Gross margin | 30.1% | 30.9% | 23.2% | 20.9% | 35.0% | 29.5% | 22.4% | 19.5% | 24.9% | 27.5% |
| Operating margin | −11.8% | −6.2% | −14.2% | −22.4% | 8.7% | 8.7% | −6.0% | −11.0% | 3.8% | 4.2% |
| Net margin | −11.9% | −6.3% | −14.7% | −24.0% | 5.8% | 7.9% | −7.0% | −13.2% | 2.1% | 4.5% |
| Free cash flow margin | −3.4% | −9.4% | −10.6% | −28.1% | −17.2% | 1.5% | −12.0% | −8.2% | −4.9% | — |
| Rule of 40 (growth + FCF margin) | 1.1% | 6.3% | 3.2% | −40.0% | 19.7% | 73.7% | 14.6% | −8.2% | 35.4% | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −45.4% | −26.2% | −90.2% | −207.7% | 46.6% | 45.5% | −43.2% | −194.8% | 20.6% | 23.1% |
| Return on assets | −27.2% | −14.2% | −32.4% | −37.7% | 8.6% | 11.1% | −8.5% | −15.2% | 2.9% | 6.1% |
| Net debt to EBITDA | — | — | — | — | 0.4x | — | — | — | — | — |